AXIM Biotechnologies (OTCMKTS:AXIM) and BioRestorative Therapies (OTCMKTS:BRTX) Critical Comparison

Profitability

This table compares AXIM Biotechnologies and BioRestorative Therapies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AXIM Biotechnologies	N/A	N/A	N/A
BioRestorative Therapies	-13,728.83%	-120.47%	-114.48%

Valuation & Earnings

This table compares AXIM Biotechnologies and BioRestorative Therapies”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AXIM Biotechnologies	N/A	N/A	N/A	($0.01)	-1.18
BioRestorative Therapies	$605,200.00	20.96	-$18.50 million	($1.27)	-1.25

AXIM Biotechnologies has higher earnings, but lower revenue than BioRestorative Therapies. BioRestorative Therapies is trading at a lower price-to-earnings ratio than AXIM Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

69.4% of BioRestorative Therapies shares are held by institutional investors. 30.8% of BioRestorative Therapies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

AXIM Biotechnologies beats BioRestorative Therapies on 5 of the 8 factors compared between the two stocks.

About AXIM Biotechnologies

AXIM Biotechnologies, Inc. engages in the development and sale of diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and other diseases. The company is developing tests for dye eye diseases; SARS-CoV-2 neutralizing antibody tests; and fentanyl neutralizing antibody tests. It also developing a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.

About BioRestorative Therapies

BioRestorative Therapies, Inc. engages in the development of therapeutic products and medical therapies using cell and tissue protocols. Its programs provide quality of care for chronic back pain caused by disc degeneration and metabolic disorders, including obesity and diabetes. The company’s initial investigational therapeutic product being called BRTX-100 focuses on treating damage by an autologous stem cell product that uses own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process. BioRestorative Therapies was founded on June 13, 1997 and is headquartered in Melville, NY.